内部人交易雷达

美国 · SEC Form 4 · 快照日期: 2026-10-18 · 构建时间: 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Alkermes plc.

ALKS · Nasdaq · CIK 0001520262 · Healthcare · Drug Manufacturers—Specialty & Generic

内部人信号

当前没有活跃买入信号

0 qualifying P purchase groups
当前 180 天评分窗口

45 同一窗口内观察到的 Form 4 交易行
17 sales · 28 期权、代扣税、授予、赠与或其他交易行

最近一次合资格买入2022-11-14 · Daglio David Angelo Jr. · $815.9K

为什么没有活跃信号?

买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成

活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。

Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算

为什么没有分数?

  • 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
  • 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。

卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。

AprMayJunJulAugSepOct
Hopkinson Craig C.EVP R&D, Chief Medical Officer
○▼○▼○▼○▼○▼
Gaffin David JosephEVP, CLO, Alkermes, Inc.
▼▼▼▼▼▼
snyderman nancy lynn MDDirector
○○○▼
Wright Christopher IDirector
○○▼
Parisi Samuel JosephVP, Finance (Interim PAO)
○▼
Wilson Frank AndersDirector
○○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 7 additional owner(s) remain in Form 4 申报证据.

买方广度、集中度与聚集买入

合资格买入进入 180 天研究窗口后,这些模块才会启用。

信号历史

暂无已记录的活跃信号快照

Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2022-11-14 · Daglio David Angelo Jr..

近期 Form 4 活动

0买入
33卖出
87其他 Form 4 交易行
58SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出17 sale line(s) · 仅供背景
其他28 exercise / withholding / award / gift / other lines
10b5-1/计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息,不影响内部人信号。

价格表现

1M
-12.4%
3M
-24.2%
6M
+20.0%
12M
—

波动率与流动性

波动率
40.5%
Beta
—
平均每日成交额
—

估值

市值
—
P/E
—

基本面

利润率
16.4%
ROE
13.3%
细分行业
Drug Manufacturers—Specialty & Generic

市场数据

价格数据截至:2026-10-02 · 价格来源:OpenBB/yfinance · 来自 SEC 申报文件:利润率, ROE · 财年截止日:2025-12-31 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。

空头股数
17,821,179
上期报告
15,156,775
日均成交量
2,839,345
回补天数
6.3

FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2022-11-14Daglio David Angelo Jr.买入 (P)Ordinary Shares35,000USD 23.31USD 815,850SEC 申报 ↗
2022-03-04snyderman nancy lynn MD买入 (P)Ordinary Shares427USD 23.43USD 10,005SEC 申报 ↗
2021-08-23Alva Emily Peterson买入 (P)Ordinary Shares1,650USD 30.22USD 49,868SEC 申报 ↗
2021-08-02MCKEON BRIAN P买入 (P)Ordinary Shares10,000USD 26.43USD 264,300SEC 申报 ↗
2020-02-24Wysenski Nancy买入 (P)Ordinary Shares6,940USD 19.65USD 136,371SEC 申报 ↗

Form 4 申报证据

120 transaction lines in the latest 365-day window; 774 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-10-08Reed Joshua期权行权/转换 (M)Ordinary Shares9,164USD —USD —SEC 申报 ↗
2026-10-08Reed Joshua代扣税 (F)Ordinary Shares4,069USD 40.11USD 163,208SEC 申报 ↗
2026-10-02Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 41.03USD 83,455SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-10-08Reed Joshua期权行权/转换 (M)Ordinary Shares9,164USD —USD —SEC 申报 ↗
2026-10-08Reed Joshua代扣税 (F)Ordinary Shares4,069USD 40.11USD 163,208SEC 申报 ↗
2026-10-02Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 41.03USD 83,455SEC 申报 ↗
2026-09-03Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 48.01USD 97,652SEC 申报 ↗
2026-09-01Hopkinson Craig C.卖出 (S)Ordinary Shares9,000USD 46.99USD 422,910SEC 申报 ↗
2026-09-01Hopkinson Craig C.期权行权/转换 (M)Ordinary Shares5,000USD 24.59USD 122,950SEC 申报 ↗
2026-08-17Nichols Christian Todd卖出 (S)Ordinary Shares7,576USD 49.23USD 372,969SEC 申报 ↗
2026-08-03snyderman nancy lynn MD卖出 (S)Ordinary Shares44,472USD 50.35USD 2,239,165SEC 申报 ↗
2026-08-03snyderman nancy lynn MD期权行权/转换 (M)Ordinary Shares44,472USD 46.72USD 2,077,732SEC 申报 ↗
2026-08-03Hopkinson Craig C.卖出 (S)Ordinary Shares9,000USD 48.58USD 437,220SEC 申报 ↗
2026-08-03Hopkinson Craig C.期权行权/转换 (M)Ordinary Shares5,000USD 24.48USD 122,404SEC 申报 ↗
2026-08-03Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 48.58USD 98,812SEC 申报 ↗
2026-07-06Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 54.03USD 109,897SEC 申报 ↗
2026-07-01Hopkinson Craig C.卖出 (S)Ordinary Shares9,000USD 51.51USD 463,609SEC 申报 ↗
2026-07-01Hopkinson Craig C.期权行权/转换 (M)Ordinary Shares5,000USD 19.34USD 96,700SEC 申报 ↗
2026-06-12Wright Christopher I卖出 (S)Ordinary Shares2,000USD 45.10USD 90,200SEC 申报 ↗
2026-06-04Gaffin David Joseph卖出 (S)Ordinary Shares2,034USD 43.05USD 87,564SEC 申报 ↗
2026-06-01Hopkinson Craig C.卖出 (S)Ordinary Shares9,000USD 41.67USD 375,030SEC 申报 ↗
2026-06-01Hopkinson Craig C.期权行权/转换 (M)Ordinary Shares5,000USD 19.34USD 96,700SEC 申报 ↗
2026-05-29Parisi Samuel Joseph卖出 (S)Ordinary Shares16,217USD 42.36USD 686,952SEC 申报 ↗
2026-05-29Parisi Samuel Joseph期权行权/转换 (M)Ordinary Shares16,217USD 19.48USD 315,977SEC 申报 ↗
2026-05-21snyderman nancy lynn MD期权行权/转换 (M)Ordinary Shares6,142USD —USD —SEC 申报 ↗
2026-05-21snyderman nancy lynn MD代扣税 (F)Ordinary Shares1,475USD 36.95USD 54,501SEC 申报 ↗
2026-05-21Wright Christopher I期权行权/转换 (M)Ordinary Shares6,142USD —USD —SEC 申报 ↗
2026-05-21Wright Christopher I代扣税 (F)Ordinary Shares1,475USD 36.95USD 54,501SEC 申报 ↗
2026-05-21Wilson Frank Anders期权行权/转换 (M)Ordinary Shares6,142USD —USD —SEC 申报 ↗
2026-05-21Wilson Frank Anders代扣税 (F)Ordinary Shares1,475USD 36.95USD 54,501SEC 申报 ↗
2026-05-21MCKEON BRIAN P期权行权/转换 (M)Ordinary Shares6,142USD —USD —SEC 申报 ↗
2026-05-21MCKEON BRIAN P代扣税 (F)Ordinary Shares1,475USD 36.95USD 54,501SEC 申报 ↗
2026-05-21Lurker Nancy期权行权/转换 (M)Ordinary Shares6,142USD —USD —SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码ALKS
CIK0001520262
行业Healthcare
细分行业Drug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所Nasdaq

数据覆盖

本地 Form 4 历史774 transaction lines from 2020-02-16 to 2026-10-08
5 P purchase lines · 109 S sale lines · 660 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.